321 related articles for article (PubMed ID: 31786130)
1. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG
Eckl-Dorna J; Weber M; Stanek V; Linhart B; Ristl R; Waltl EE; Villazala-Merino S; Hummel A; Focke-Tejkl M; Froeschel R; Neubauer A; Henning R; Perkmann T; Valenta R; Niederberger V
EBioMedicine; 2019 Dec; 50():421-432. PubMed ID: 31786130
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy.
Zieglmayer P; Focke-Tejkl M; Schmutz R; Lemell P; Zieglmayer R; Weber M; Kiss R; Blatt K; Valent P; Stolz F; Huber H; Neubauer A; Knoll A; Horak F; Henning R; Valenta R
EBioMedicine; 2016 Sep; 11():43-57. PubMed ID: 27650868
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32.
Niederberger V; Neubauer A; Gevaert P; Zidarn M; Worm M; Aberer W; Malling HJ; Pfaar O; Klimek L; Pfützner W; Ring J; Darsow U; Novak N; Gerth van Wijk R; Eckl-Dorna J; Focke-Tejkl M; Weber M; Müller HH; Klinger J; Stolz F; Breit N; Henning R; Valenta R
J Allergy Clin Immunol; 2018 Aug; 142(2):497-509.e9. PubMed ID: 29361332
[TBL] [Abstract][Full Text] [Related]
4. Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32.
Tulaeva I; Cornelius C; Zieglmayer P; Zieglmayer R; Schmutz R; Lemell P; Weber M; Focke-Tejkl M; Karaulov A; Henning R; Valenta R
EBioMedicine; 2020 Sep; 59():102953. PubMed ID: 32855110
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy.
Focke-Tejkl M; Weber M; Niespodziana K; Neubauer A; Huber H; Henning R; Stegfellner G; Maderegger B; Hauer M; Stolz F; Niederberger V; Marth K; Eckl-Dorna J; Weiss R; Thalhamer J; Blatt K; Valent P; Valenta R
J Allergy Clin Immunol; 2015 May; 135(5):1207-7.e1-11. PubMed ID: 25441634
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection.
Cornelius C; Schöneweis K; Georgi F; Weber M; Niederberger V; Zieglmayer P; Niespodziana K; Trauner M; Hofer H; Urban S; Valenta R
EBioMedicine; 2016 Sep; 11():58-67. PubMed ID: 27568223
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
9. Induction of antibody responses to new B cell epitopes indicates vaccination character of allergen immunotherapy.
Ball T; Sperr WR; Valent P; Lidholm J; Spitzauer S; Ebner C; Kraft D; Valenta R
Eur J Immunol; 1999 Jun; 29(6):2026-36. PubMed ID: 10382766
[TBL] [Abstract][Full Text] [Related]
10. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
11. Nasal allergen-neutralizing IgG
Shamji MH; Kappen J; Abubakar-Waziri H; Zhang J; Steveling E; Watchman S; Kouser L; Eifan A; Switzer A; Varricchi G; Marone G; Couto-Francisco NC; Calderon M; Durham SR
J Allergy Clin Immunol; 2019 Mar; 143(3):1067-1076. PubMed ID: 30445057
[TBL] [Abstract][Full Text] [Related]
12. Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy.
Linhart B; Focke-Tejkl M; Weber M; Narayanan M; Neubauer A; Mayrhofer H; Blatt K; Lupinek C; Valent P; Valenta R
J Immunol; 2015 Apr; 194(8):4008-18. PubMed ID: 25786690
[TBL] [Abstract][Full Text] [Related]
13. Human leukocyte antigen-G and regulatory T cells during specific immunotherapy for pollen allergy.
Sørensen AE; Johnsen CR; Dalgaard LT; Würtzen PA; Kristensen B; Larsen MH; Ullum H; Søes-Petersen U; Hviid TV
Int Arch Allergy Immunol; 2013; 162(3):237-52. PubMed ID: 24022071
[TBL] [Abstract][Full Text] [Related]
14. A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype.
Marth K; Breyer I; Focke-Tejkl M; Blatt K; Shamji MH; Layhadi J; Gieras A; Swoboda I; Zafred D; Keller W; Valent P; Durham SR; Valenta R
J Immunol; 2013 Apr; 190(7):3068-78. PubMed ID: 23440415
[TBL] [Abstract][Full Text] [Related]
15. Poor association of allergen-specific antibody, T- and B-cell responses revealed with recombinant allergens and a CFSE dilution-based assay.
Eckl-Dorna J; Campana R; Valenta R; Niederberger V
Allergy; 2015 Oct; 70(10):1222-9. PubMed ID: 26043182
[TBL] [Abstract][Full Text] [Related]
16. Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG
Köhler VK; Crescioli S; Fazekas-Singer J; Bax HJ; Hofer G; Pranger CL; Hufnagl K; Bianchini R; Flicker S; Keller W; Karagiannis SN; Jensen-Jarolim E
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32784509
[TBL] [Abstract][Full Text] [Related]
17. Allergome-wide peptide microarrays enable epitope deconvolution in allergen-specific immunotherapy.
Mikus M; Zandian A; Sjöberg R; Hamsten C; Forsström B; Andersson M; Greiff L; Uhlén M; Levin M; Nilsson P; van Hage M; Ohlin M
J Allergy Clin Immunol; 2021 Mar; 147(3):1077-1086. PubMed ID: 32791163
[TBL] [Abstract][Full Text] [Related]
18. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy.
Shamji MH; Ljørring C; Francis JN; Calderon MA; Larché M; Kimber I; Frew AJ; Ipsen H; Lund K; Würtzen PA; Durham SR
Allergy; 2012 Feb; 67(2):217-26. PubMed ID: 22077562
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines.
Weber M; Niespodziana K; Linhart B; Neubauer A; Huber H; Henning R; Valenta R; Focke-Tejkl M
J Allergy Clin Immunol; 2017 Nov; 140(5):1433-1436.e6. PubMed ID: 28576673
[No Abstract] [Full Text] [Related]
20. Detection of pan-allergens in commercial pollen extracts for allergen immunotherapy.
Asero R; Mistrello G; Amato S
Ann Allergy Asthma Immunol; 2016 Aug; 117(2):180-5. PubMed ID: 27238577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
